Barinthus Biotherapeutics (BRNS) Other Accumulated Expenses (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has 4 years of Other Accumulated Expenses data on file, last reported at $1.3 million in Q3 2023.

• Quarterly Other Accumulated Expenses fell 50.17% year-over-year to $1.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $1.3 million (down 50.17% YoY) and the FY2022 annual result came in at $932000.0, down 25.56% from the prior year.
• Other Accumulated Expenses grew to $1.3 million in Q3 2023, from $638000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2022 to a low of $46000.0 in Q2 2021.
• A 4-year average of $922818.2 and a median of $932000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 2091.3% — and 2023, when it sank 50.17%.
• Tracing BRNS's Other Accumulated Expenses over 4 years: stood at $266000.0 in 2020, then jumped by 370.68% to $1.3 million in 2021, then dropped by 25.56% to $932000.0 in 2022, then jumped by 41.09% to $1.3 million in 2023.
• The last three Other Accumulated Expenses figures came in at $1.3 million (Q3 2023), $638000.0 (Q2 2023), and $932000.0 (Q4 2022), per Business Quant data.